Company Overview - Indaptus Therapeutics, Inc. is focused on immunotherapy, leveraging over a century of advancements in the field [3] - The company's approach involves activating both innate and adaptive immune cells through a multi-targeted package of immune system-activating signals that can be administered safely via intravenous (i.v.) methods [3] - Indaptus' patented technology utilizes non-pathogenic Gram-negative bacteria to produce a Decoy platform that acts as agonists for multiple immune receptors [3] Product Development - The Decoy product candidates have shown single-agent activity against various cancers, including metastatic pancreatic and colorectal carcinomas, and have demonstrated combination-mediated eradication of hepatocellular carcinomas and non-Hodgkin's lymphomas in pre-clinical models [5] - Pre-clinical studies indicate that these candidates can induce immunological memory and activate immune pathways with just one i.v. dose, transitioning tumors from a "cold" to a "hot" inflammation signature [5] - The Decoy candidates have also shown efficacy against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in pre-clinical models [5] Upcoming Events - CEO Jeffrey Meckler will present at Tribe Public's Webinar titled "Keys To The Kingdom: Unlocking The Power Of Your Immune System" on March 17, 2025 [1] - Participants can submit questions for the CEO during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [2]
Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025